New Postmenopausal Vaginal Atrophy Therapeutics to Provide Boost for Market Growth and Female Libido

Tuesday 25 February 2014, Amsterdam

The Postmenopausal Vaginal Atrophy (PVA) therapeutics market will double from $1 billion to approximately $2 billion over the next decade, with the US being the largest global contributor.

The company’s latest report states that between 2012 and 2022, the global PVA therapeutics market will grow at a Compound Annual Growth Rate (CAGR) of 6%. This will be backed significantly by the US market, which will climb from $976 million to $1.9 billion over the 10-year period, at a CAGR of 6.3%.  

Combined, the UK, France, Germany, Italy and Spain are expected to follow with a PVA therapeutics market revenue of $149 million in 2022, while the Japanese market will reach a value of $20 million by the same year.  

The launch of Shionogi’s Osphena, which is a treatment for the large number of women suffering from dyspareunia, a prevalent symptom of PVA, is expected to be a significant market-driving force across these seven major markets in 2013.  

Meanwhile, Vaginorm could well dominate the global PVA market thanks to its potential of being black box warning-free, as well as its claims of helping to bolster female libido.  

Anita Angelica Moore, the Therapy Analyst covering Oncology and Women’s Health, says: “Although the PVA market has experienced anemic growth over the past decade, it is expected to undergo considerable changes spurred by the launch of these products by 2014.

“The marketing efforts surrounding these treatments will help to raise awareness of the condition and increase the patient pool, as previously-untreated women seek out further information from their physicians.”

Despite the fact that these pipeline drugs present arguably better safety profiles than systemic estrogen therapies, they still carry a number of concerns, which presents an ideal opportunity for drug developers to create safer solutions and therefore fulfill this unmet need in the market, according to the report.